Nausea (most common, typically dose-dependent and transient) Diarrhea or constipation during dose escalation Vomiting, especially when starting or increasing dose Reduced appetite and early satiety Injection site reactions (redness, bruising) Fatigue, particularly in early weeks Rare: Pancreatitis discontinue immediately with severe abdominal pain Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history) AOD-9604 is a modified C-terminal fragment (residues 176191, Tyr-hGH177-191) of human growth hormone, studied for lipolytic and anti-obesity properties
It is the most clinically studied of the three, with topical trials showing collagen, fine-line, and skin-density changes, and a large body of in-vitro work on gene expression and wound healing
Much of the research on BPC-157 to date has been done in laboratory animals, but researchers are now using the findings to date to help direct further research into the ways BPC-157 may be beneficial for human subjects
The convenience of a single injection appeals to many patients